Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Revolution Medicines (RVMD) Interest Expenses (2019 - 2025)

Revolution Medicines has reported Interest Expenses over the past 5 years, most recently at -$12.3 million for Q4 2025.

  • Quarterly results put Interest Expenses at -$12.3 million for Q4 2025, down 584.89% from a year ago — trailing twelve months through Dec 2025 was -$830000.0 (down 115.55% YoY), and the annual figure for FY2025 was $37000.0, down 98.54%.
  • Interest Expenses for Q4 2025 was -$12.3 million at Revolution Medicines, down from $11.4 million in the prior quarter.
  • Over the last five years, Interest Expenses for RVMD hit a ceiling of $11.4 million in Q3 2025 and a floor of -$12.3 million in Q4 2025.
  • Median Interest Expenses over the past 3 years was $2.5 million (2024), compared with a mean of $903800.0.
  • Biggest five-year swings in Interest Expenses: crashed 42.86% in 2021 and later tumbled 584.89% in 2025.
  • Revolution Medicines' Interest Expenses stood at $12000.0 in 2021, then skyrocketed by 20966.67% to $2.5 million in 2024, then tumbled by 584.89% to -$12.3 million in 2025.
  • The last three reported values for Interest Expenses were -$12.3 million (Q4 2025), $11.4 million (Q3 2025), and $2.5 million (Q4 2024) per Business Quant data.